An update on diabetes spectrum in heart failure: current evidence and potential therapeutic applications

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Diseases

Background:

• Diabetes and heart failure (HF) frequently coexist, posing significant clinical challenges.
• Current treatment evidence often relies on post hoc analyses of trials and registries.
• Emerging data highlight the cardiovascular benefits of novel antidiabetic medications.

Purpose of the Study:

• To review cardiovascular outcome trials of newer antidiabetic agents in patients with diabetes and HF.
• To explore the efficacy of these agents in specific populations, including the elderly, HF with preserved ejection fraction (HFpEF), and pulmonary hypertension.
• To discuss the impact of these drugs on muscle, pulmonary, and renal metabolism.

Main Methods:

• Summary of key findings from major cardiovascular outcome trials.
• Analysis of data stratified by patient subgroups and specific conditions.
• Review of mechanisms underlying the cardioprotective effects of antidiabetic drugs.

Main Results:

• Newer antidiabetic agents demonstrate a significant reduction in HF-related events.
• Evidence supports their use beyond traditional glucose-lowering effects.
• Specific benefits are noted in elderly patients, those with HFpEF, and individuals with pulmonary hypertension.

Conclusions:

• Novel antidiabetic drugs represent a crucial therapeutic advancement for patients with comorbid diabetes and HF.
• Their use should be considered for their cardiovascular benefits, particularly in high-risk populations.
• Further research into metabolic effects may reveal additional therapeutic targets.